The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in adults.

Brazilian researchers have developed a cell phone application that helps rehabilitate people who have suffered a stroke.

The FDA has approved TNKase, a new, fast-acting stroke treatment that dissolves blood clots more efficiently, marking a significant advancement in stroke therapy and clot-busting technology.

TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second ...

The FDA has approved TNKase, a tissue plasminogen, clot-dissolving agent, to treat acute ischemic stroke in adults, according ...

A stroke may happen without any warning, but in some cases, you may be experiencing symptoms and not even realize it -- here ...

Genentech has had the lone medicine on the market for the acute treatment of stroke. | Over nearly the last three decades, ...

The Vanderbilt Rehabilitation Center (VRC) at Newport Hospital provides specialized care and support for stroke patients. VRC ...

The following is a summary of “Reducing time delays and enhancing reperfusion eligibility related to stroke suspicion by the ...

According to Roche subsidiary Genentech, which announced the label expansion on Monday, TNKase is the first new drug for ...

(HealthDay News) — The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.

TNKase is administered as a single intravenous bolus over 5 seconds. The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS ...